Tag: Regulatory Stability Guidelines

How to Design Stability Studies for Combination Products as per Regulatory Guidelines Creating Stability Studies for Combination Products: A Regulatory Perspective Introduction Combination products, which include a combination of drug, device, or biological products, pose unique challenges for stability testing. Regulatory authorities such as the US FDA and EMA have specific guidelines for conducting stability…

Read More “How to Design Stability Studies for Combination Products as per Regulatory Guidelines” »

How to Implement ICH Q1E for Stability Data Evaluation Applying ICH Q1E Guidelines for Effective Stability Data Evaluation Introduction The ICH Q1E guideline provides recommendations on the evaluation and extrapolation of stability data to support the shelf life of drug substances and products. Proper implementation of these guidelines ensures that stability data is interpreted correctly…

Read More “How to Implement ICH Q1E for Stability Data Evaluation” »

How to Conduct Stability Studies for Drug Substances Under US FDA Guidelines Stability Testing of Drug Substances as per US FDA Requirements Introduction Stability studies for drug substances are essential to demonstrate that the active pharmaceutical ingredient (API) remains stable and maintains its intended quality, safety, and efficacy over its shelf life. The US FDA…

Read More “How to Conduct Stability Studies for Drug Substances Under US FDA Guidelines” »

How to Develop a Stability-Indicating Method in Compliance with ICH Q2(R1) Creating Stability-Indicating Methods According to ICH Q2(R1) Guidelines Introduction A stability-indicating method is a validated analytical procedure that accurately and precisely measures active ingredients, excipients, and degradation products to assess the stability of a drug substance or product. The ICH Q2(R1) guideline outlines the…

Read More “How to Develop a Stability-Indicating Method in Compliance with ICH Q2(R1)” »

How to Address Stability Issues in ANDA Submissions to the US FDA Handling Stability Challenges in ANDA Submissions to the FDA Introduction Abbreviated New Drug Application (ANDA) submissions to the US FDA require comprehensive stability data to demonstrate that a generic drug product meets the same quality, safety, and efficacy standards as its reference listed…

Read More “How to Address Stability Issues in ANDA Submissions to the US FDA” »

How to Conduct Stability Studies for Biologics Following FDA Guidelines Guidelines for Stability Testing of Biologics as per FDA Requirements Introduction Biologics, or biological products, require rigorous stability studies to ensure their safety, efficacy, and quality over their shelf life due to their complex nature and sensitivity to environmental factors. The US FDA provides specific…

Read More “How to Conduct Stability Studies for Biologics Following FDA Guidelines” »

How to Implement Stability Studies for Drug Products in Compliance with US FDA CFR Title 21 Conducting Stability Studies for Drug Products as per US FDA CFR Title 21 Requirements Introduction Stability studies are essential for ensuring that drug products meet their quality, safety, and efficacy standards throughout their shelf life. The US Food and…

Read More “How to Implement Stability Studies for Drug Products in Compliance with US FDA CFR Title 21” »